Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.
Why Abbvie May Have A Tough Time Defending Humira’s Price Before Congress
Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.